article thumbnail

Humira generic availability, cost, and dosage

The Checkup by Singlecare

The pharmaceutical company that makes Amjevita is called Amgen, Inc. It was FDA approved in August 2017 as a biosimilar, approved in 2021 as an interchangeable biosimilar, and became available in the United States in July of 2023. The pharmaceutical company that makes Cyltezo is called Boehringer Ingelheim Pharmaceuticals, Inc.

Dosage 97
article thumbnail

Eliquis generic availability, cost, and dosage

The Checkup by Singlecare

However, pharmaceutical companies Bristol-Myers Squibb and Pfizer filed lawsuits to delay these generic manufacturers from bringing apixaban generics to the market. In 2021, the Bristol Myers Squibb-Pfizer Alliance announced that the U.S. The post Eliquis generic availability, cost, and dosage appeared first on The Checkup.

Dosage 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

OSD contract manufacturing market valued at $54.7 billion by 2030

European Pharmaceutical Review

A market report has projected that the global oral solid dosage (OSD) contract manufacturing market is expected to be worth $54.7 Slow-release formulations were a popular choice for manufacturers, as these varieties reduce the traditional dosage frequency for patients, who only need to take these medications say, once a week.

Dosage 82
article thumbnail

Amarin Makes Moves towards Global Expansion of Vazkepa

Pharmaceutical Technology

The pharmaceutical company is well on its way to achieving its goals with successful full reimbursements, already confirmed in the United Kingdom ( UK), and Sweden. million in 2021 and $607 million in 2020, as per its financial filings. The company’s market cap is $455.6 per 1,000mg dosage compared to Amarin’s $4.14

article thumbnail

The critical role of the generics sector during the pandemic

pharmaphorum

There is a long-established synergistic relationship between larger, “innovation-driven” pharmaceutical companies and the generics industry in ensuring supply of established, but nevertheless essential, medicines. The pandemic has further highlighted how research is not strictly limited to large, “innovator” pharmaceutical companies.

article thumbnail

Patents: a necessary evil?

European Pharmaceutical Review

Patents are often described as the ‘lifeblood’ of pharmaceutical companies. 1 However, patent protection for pharmaceutical products is an economic trade-off between providing monopoly rights that incentivise development of future products and permitting higher drug prices to recoup the investment. September 10, 2021.

FDA 73
article thumbnail

Top 20 Radiopharma Companies Based on Market Cap

PharmaShots

Market Cap: $21.06M Founded Year: 2021 Total Employees: ~10 Headquarters: Victoria, Australia Stock Exchange: ASX Radiopharm Theranostics is a biotech company focused on developing radiopharmaceuticals for diagnosing and treating diseases with high unmet medical needs. In 2021, Xofigo generated a sale of $75.08M.

FDA 56